Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Severe Aplastic Anemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: Severe Aplastic Anemia. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2022-001257-22 Sponsor Protocol Number: 20210112 Start Date*: 2023-03-29
    Sponsor Name:Amgen, Inc.
    Full Title: Two Arm Bridging Study to Evaluate the Efficacy of Romiplostim in the Treatment of Non Asian Adult Severe Aplastic Anemia (SAA) Subjects who are Either Previously Untreated With Immunosuppressive T...
    Medical condition: Aplastic anemia (AA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    20.1 10005329 - Blood and lymphatic system disorders 10002968 Aplastic anaemia, unspecified LLT
    23.0 10005329 - Blood and lymphatic system disorders 10083893 Acquired aplastic anaemia LLT
    20.0 10005329 - Blood and lymphatic system disorders 10032510 Other specified aplastic anaemias LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002969 Aplastic anemia LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002037 Anaemia aplastic LLT
    20.0 10005329 - Blood and lymphatic system disorders 10002274 Anemia aplastic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000902-55 Sponsor Protocol Number: RATGAA07 Start Date*: 2007-09-19
    Sponsor Name:EBMT (European group for Blood and Marrow Transplantation)
    Full Title: Prospective Phase II study of Rabbit Antithymocyte globulin (ATG, Thymoglobuline®, Genzyme) with Ciclosporin for Patients with Acquired Aplastic Anaemia and comparison with matched historical patie...
    Medical condition: Acquired severe aplastic anaemia and transfusion dependent non-severe aplastic anaemia
    Disease: Version SOC Term Classification Code Term Level
    14.0 10005329 - Blood and lymphatic system disorders 10002274 Anemia aplastic LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000363-40 Sponsor Protocol Number: 8409032 Start Date*: 2016-01-07
    Sponsor Name:European Society for Blood and Marrow Transplantation
    Full Title: A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients.
    Medical condition: Idiopathic (Severe) Aplastic Anemia, a bone marrow failure syndrome which results in the normal hematopoietic tissue completely missing from the bone marrow, accounting for the subsequent pancytope...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2024-000602-14 Sponsor Protocol Number: CETB115G2201 Start Date*: 2025-05-28
    Sponsor Name:Novartis
    Full Title: A non-randomized, open label, multi-center, Phase II study to assess the safety and efficacy of eltrombopag in combination with rabbit anti-thymocyte globulin (r-ATG) and cyclosporine A (CsA) in Ea...
    Medical condition: treatment naive severe aplastic anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002969 Aplastic anemia LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001151-22 Sponsor Protocol Number: Alesaa Start Date*: 2007-06-06
    Sponsor Name:UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO II
    Full Title: ALEMTUZUMAB AND LOW-DOSE CYCLOSPORINE-A AS ALTERNATIVE IMMUNOSUPPRESSIVE TREATMENT FOR SEVERE APLASTIC ANEMIA (SAA) AND SINGLE-LINEAGE APLASTIC PATIENTS.
    Medical condition: Aplastic anemia and single-lineage bone marrow failure
    Disease: Version SOC Term Classification Code Term Level
    13.1 10005329 - Blood and lymphatic system disorders 10002965 Aplasia pure red cell PT
    13.1 10005329 - Blood and lymphatic system disorders 10047350 Very few granulocyte precursors LLT
    13.1 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    13.1 10005329 - Blood and lymphatic system disorders 10001507 Agranulocytosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002814-29 Sponsor Protocol Number: CETB115E2403 Start Date*: 2017-03-21
    Sponsor Name:Novartis Farmacéutica, S.A
    Full Title: SOAR Trial, A two-part study: Interventional phase II single-arm trial to assess efficacy and safety of Eltrombopag combined with cyclosporine as first line therapy in patients with severe acquired...
    Medical condition: First-line severe aplastic anaemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted) NL (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003166-91 Sponsor Protocol Number: CETB115E2201 Start Date*: 2019-05-22
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, rela...
    Medical condition: Refractory, relapsed or treatment naïve severe aplastic anemia (SAA) or recurrent aplastic anemia (AA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10002967 Aplastic anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PT (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-002031-29 Sponsor Protocol Number: R7257-RAA-1947 Start Date*: 2020-11-05
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A PHASE 1/2 STUDY OF REGN7257 (ANTI-INTERLEUKIN 2 RECEPTOR SUBUNIT GAMMA [IL2RG] MONOCLONAL ANTIBODY) IN PATIENTS WITH SEVERE APLASTIC ANEMIA THAT IS REFRACTORY TO OR RELAPSED ON IMMUNOSUPPRESSIVE ...
    Medical condition: SEVERE APLASTIC ANEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002274 Anemia aplastic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004364-35 Sponsor Protocol Number: CETB115AUS01T Start Date*: 2018-07-25
    Sponsor Name:National Heart, Lung, and Blood
    Full Title: Eltrombopag added to standard immunosuppression in treatment-naïve severe aplastic anemia.
    Medical condition: Severe aplastic anemia (SAA)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2018-002935-88 Sponsor Protocol Number: VX18-CTX001-131 Start Date*: 2019-03-13
    Sponsor Name:Vertex Pharmaceuticals Incorporated
    Full Title: A Long-term Follow-up Study of Subjects With β-thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 Modified Hematopoietic Stem Cells (CTX001)
    Medical condition: Transfusion-dependent β thalassemia (TDT). Severe sickle cell disease (SCD).
    Disease: Version SOC Term Classification Code Term Level
    26.1 10010331 - Congenital, familial and genetic disorders 10043391 Thalassaemia beta PT
    21.0 10010331 - Congenital, familial and genetic disorders 10040641 Sickle cell anaemia PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) FR (Ongoing) GR (Prematurely Ended) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003226-16 Sponsor Protocol Number: BP-404 Start Date*: 2017-02-03
    Sponsor Name:Bellicum Pharmaceuticals, Inc.
    Full Title: Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders
    Medical condition: Hematological disorders (ALL;AML;Non-Hodgkin lymphoma;Myelodysplastic syndromes;Congenital immune deficiencies;Severe aplastic anemia;Fanconi anemia; Osteopetrosis;Selected cases of hemoglobinopath...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10005329 - Blood and lymphatic system disorders 10018849 Haematological disorders NEC HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-000393-76 Sponsor Protocol Number: ZKI-SCT-HAPLO-0106 Start Date*: 2006-10-25
    Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt am Main
    Full Title: Allogenic stem cell transplantation with CD3/CD19 depleted stem cells from haploidentical related and non-related donators in pediatric patients with and without malignant systemic diseases.
    Medical condition: Pediatric patients with malignant and non-malignant high-risk diseases, where the allogeneic stem cell transplantation represents the only option for a curative therapy and where an adequate HLA-id...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003435-11 Sponsor Protocol Number: VL2397-201 Start Date*: 2018-08-14
    Sponsor Name:Vical Incorporated
    Full Title: A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Immunocompromised Adults
    Medical condition: Invasive Aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10051597 Cerebral aspergillosis PT
    20.1 10021881 - Infections and infestations 10006473 Bronchopulmonary aspergillosis PT
    20.0 10021881 - Infections and infestations 10003490 Aspergillosis pharyngeal LLT
    20.1 10021881 - Infections and infestations 10022881 Invasive bronchopulmonary aspergillosis LLT
    20.0 10021881 - Infections and infestations 10059259 Pulmonary aspergillosis LLT
    20.0 10021881 - Infections and infestations 10003488 Aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000584-41 Sponsor Protocol Number: BP-004 Start Date*: 2014-10-23
    Sponsor Name:Bellicum Pharmaceuticals, Inc.
    Full Title: Phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders
    Medical condition: Hematological disorders (ALL;AML;Non-Hodgkin lymphoma;Myelodysplastic syndromes;Congenital immune deficiencies;Severe aplastic anemia;Fanconi anemia; Osteopetrosis;Selected cases of hemoglobinopath...
    Disease: Version SOC Term Classification Code Term Level
    16.1 10005329 - Blood and lymphatic system disorders 10018849 Haematological disorders NEC HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005594-35 Sponsor Protocol Number: TJB0603 Start Date*: 2009-10-28
    Sponsor Name:CHU Sart-Tilman
    Full Title: Randomized double-blind study of mesenchymal stem cells (MSC) in patients undergoing matched unrelated allogeneic bone marrow or peripheral blood stem cell transplantation- A European multicentre s...
    Medical condition: Hematological disorders of the following types: ALL: acute lymphoblastic leukemia in complete remission (<5% blasts in marrow) up to and including third remission (excluding relapse). AML: acute my...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027703 Mismatched donor bone marrow transplantation therapy LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006577-25 Sponsor Protocol Number: 070101 Start Date*: 2007-07-25
    Sponsor Name:Karolinska Institutet
    Full Title: A prospective randomized study comparing rapamune and tacrolimus vs. cyclosporine and methotrexate as immune prophylaxis in allogeneic hematopoietic stem cell transplantation, using HLA-A, -B, -DRB...
    Medical condition: Graft versus host disease prophylaxis in patients receiving stem cell transplantation due to: chronic myeloid leukemia (CML) in 1st or 2nd chronic phase, acute myeloid leukemia (AML) in complete re...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018799 GVHD LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-004645-15 Sponsor Protocol Number: P03579 Start Date*: 2008-03-14
    Sponsor Name:Schering Plough Research Institute
    Full Title: Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia
    Medical condition: treatment and prophylaxis of invasive fungal infections; oropharyngeal candidiasis (OPC) and refractory OPC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050346 Oropharyngeal candidiasis LLT
    9.1 10017528 Fungal infectious disorders HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005862-30 Sponsor Protocol Number: MHH-Pre-GvHD-001 Start Date*: 2009-02-23
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Pre-emptive therapy of acute graft versus host disease according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation.
    Medical condition: Pre-emptive therapy of acute graft versus host disease with prednisolone according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004870 10018652 Graft versus host reaction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001489-41 Sponsor Protocol Number: P00003466 Start Date*: 2018-07-02
    Sponsor Name:Karolinska Universitetssjukhuset
    Full Title: Radiation- and alkylator-free hematopoietic cell transplantation for bone marrow failure due to dyskeratosis congenita / telomere disease
    Medical condition: Dyskeratosis congenita / telomere disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10001756 Allogenic bone marrow transplantation therapy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002565-18 Sponsor Protocol Number: SCY-078-206 Start Date*: 2019-10-04
    Sponsor Name:SCYNEXIS, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 with Voriconazole in Patients with Invasive Pulmonary Aspergillosis (SCYNERGIA)
    Medical condition: Patients with Invasive Pulmonary Aspergillosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10059259 Pulmonary aspergillosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 05:33:26 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA